cdna for human edil3 (encoding del-1) Search Results


gene exp edil3 mm01291247 m1  (Thermo Fisher)
93
Thermo Fisher gene exp edil3 mm01291247 m1
(A) DEL1 mRNA expression determined by qPCR and DEL-1 protein levels determined by ELISA in control or GHSR siRNA-transfected HMVECs treated with ERM (10 μg/mL) or ghrelin (5 μg/mL) 3 hours (mRNA) or 6 hours (protein) (n = 6 culture sets/group). Data normalized against GAPDH mRNA are expressed as fold induction relative to ethanol (set as 1). (B) HMVECs, pretreated for 24 hours with control or GHSR siRNA (20 nM), were incubated with ERM and assayed for phosphorylation at indicated points. (C) After 1-hour pretreatment with AG490 (10 μM), LY294002 (20 μM), or SB203580 (10 μM), HMVECs were incubated 3 hours with ERM and assayed for DEL1 expression (n = 6 culture sets/group). Data normalized against GAPDH mRNA were expressed as fold induction relative to ethanol control (set as 1). (D) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid, pretreated 1 hour with inhibitors, and subsequently incubated 8 hours with ERM or control followed by luciferase assay. Data are presented as fold change relative to ethanol control, set as 1 (n = 6 culture sets/group). (E) HMVECs, pretreated as above with inhibitors, were incubated 4 hours with ERM and subjected to ChIP analysis of C/EBPβ occupancy at the <t>EDIL3</t> promoter (n = 4 culture sets/group). (F) After 30-minute pretreatment with ERM or RvD1 (100 nM), HMVECs were stimulated (3 hours), or not, with IL-17 (5 ng/mL). DEL1 mRNA expression was assayed and presented as above (n = 6 HMVEC culture sets/group). (G) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid and pretreated with inhibitors. After 1 hour, the cells were treated with ERM, RvD1, or control for 30 minutes, followed by 8-hour stimulation with IL-17 and luciferase activity assay (n = 6 culture sets/group). Data are presented as fold change relative to ethanol (set as 1). (H) After 1-hour pretreatment with inhibitors, HMVECs were treated with ERM, RvD1, or ethanol for 30 minutes, followed by 4-hour stimulation with IL-17. Chromatin was immunoprecipitated with anti–C/EBPβ IgG and subjected to qPCR of the DEL1 promoter. Nonimmunoprecipitated cell extracts served as input samples. (I) After 1-hour pretreatment with inhibitors, HMVECs were incubated with RvD1 or ERM for 30 minutes and assayed for phosphorylation. In experiments shown in A–I, sequential treatments were performed without intermediate washing steps. Each compound was used at the same concentration in all experiments. Data are shown as means ± SD. **P < 0.001, ***P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (A and C–H).
Gene Exp Edil3 Mm01291247 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/Gene+Exp%2E+Edil3%2C+Mm01291247_m1/pmc07455085-484-33-51
Average 93 stars, based on 1 article reviews
gene exp edil3 mm01291247 m1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
rabbit anti edil3  (Proteintech)
91
Proteintech rabbit anti edil3
(A) DEL1 mRNA expression determined by qPCR and DEL-1 protein levels determined by ELISA in control or GHSR siRNA-transfected HMVECs treated with ERM (10 μg/mL) or ghrelin (5 μg/mL) 3 hours (mRNA) or 6 hours (protein) (n = 6 culture sets/group). Data normalized against GAPDH mRNA are expressed as fold induction relative to ethanol (set as 1). (B) HMVECs, pretreated for 24 hours with control or GHSR siRNA (20 nM), were incubated with ERM and assayed for phosphorylation at indicated points. (C) After 1-hour pretreatment with AG490 (10 μM), LY294002 (20 μM), or SB203580 (10 μM), HMVECs were incubated 3 hours with ERM and assayed for DEL1 expression (n = 6 culture sets/group). Data normalized against GAPDH mRNA were expressed as fold induction relative to ethanol control (set as 1). (D) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid, pretreated 1 hour with inhibitors, and subsequently incubated 8 hours with ERM or control followed by luciferase assay. Data are presented as fold change relative to ethanol control, set as 1 (n = 6 culture sets/group). (E) HMVECs, pretreated as above with inhibitors, were incubated 4 hours with ERM and subjected to ChIP analysis of C/EBPβ occupancy at the <t>EDIL3</t> promoter (n = 4 culture sets/group). (F) After 30-minute pretreatment with ERM or RvD1 (100 nM), HMVECs were stimulated (3 hours), or not, with IL-17 (5 ng/mL). DEL1 mRNA expression was assayed and presented as above (n = 6 HMVEC culture sets/group). (G) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid and pretreated with inhibitors. After 1 hour, the cells were treated with ERM, RvD1, or control for 30 minutes, followed by 8-hour stimulation with IL-17 and luciferase activity assay (n = 6 culture sets/group). Data are presented as fold change relative to ethanol (set as 1). (H) After 1-hour pretreatment with inhibitors, HMVECs were treated with ERM, RvD1, or ethanol for 30 minutes, followed by 4-hour stimulation with IL-17. Chromatin was immunoprecipitated with anti–C/EBPβ IgG and subjected to qPCR of the DEL1 promoter. Nonimmunoprecipitated cell extracts served as input samples. (I) After 1-hour pretreatment with inhibitors, HMVECs were incubated with RvD1 or ERM for 30 minutes and assayed for phosphorylation. In experiments shown in A–I, sequential treatments were performed without intermediate washing steps. Each compound was used at the same concentration in all experiments. Data are shown as means ± SD. **P < 0.001, ***P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (A and C–H).
Rabbit Anti Edil3, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/EDIL3+Antibody/pmc10545487__mmc2-666-18-22
Average 91 stars, based on 1 article reviews
rabbit anti edil3 - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
human edil3 duoset elisa  (R&D Systems)
94
R&D Systems human edil3 duoset elisa
(A) DEL1 mRNA expression determined by qPCR and DEL-1 protein levels determined by ELISA in control or GHSR siRNA-transfected HMVECs treated with ERM (10 μg/mL) or ghrelin (5 μg/mL) 3 hours (mRNA) or 6 hours (protein) (n = 6 culture sets/group). Data normalized against GAPDH mRNA are expressed as fold induction relative to ethanol (set as 1). (B) HMVECs, pretreated for 24 hours with control or GHSR siRNA (20 nM), were incubated with ERM and assayed for phosphorylation at indicated points. (C) After 1-hour pretreatment with AG490 (10 μM), LY294002 (20 μM), or SB203580 (10 μM), HMVECs were incubated 3 hours with ERM and assayed for DEL1 expression (n = 6 culture sets/group). Data normalized against GAPDH mRNA were expressed as fold induction relative to ethanol control (set as 1). (D) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid, pretreated 1 hour with inhibitors, and subsequently incubated 8 hours with ERM or control followed by luciferase assay. Data are presented as fold change relative to ethanol control, set as 1 (n = 6 culture sets/group). (E) HMVECs, pretreated as above with inhibitors, were incubated 4 hours with ERM and subjected to ChIP analysis of C/EBPβ occupancy at the <t>EDIL3</t> promoter (n = 4 culture sets/group). (F) After 30-minute pretreatment with ERM or RvD1 (100 nM), HMVECs were stimulated (3 hours), or not, with IL-17 (5 ng/mL). DEL1 mRNA expression was assayed and presented as above (n = 6 HMVEC culture sets/group). (G) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid and pretreated with inhibitors. After 1 hour, the cells were treated with ERM, RvD1, or control for 30 minutes, followed by 8-hour stimulation with IL-17 and luciferase activity assay (n = 6 culture sets/group). Data are presented as fold change relative to ethanol (set as 1). (H) After 1-hour pretreatment with inhibitors, HMVECs were treated with ERM, RvD1, or ethanol for 30 minutes, followed by 4-hour stimulation with IL-17. Chromatin was immunoprecipitated with anti–C/EBPβ IgG and subjected to qPCR of the DEL1 promoter. Nonimmunoprecipitated cell extracts served as input samples. (I) After 1-hour pretreatment with inhibitors, HMVECs were incubated with RvD1 or ERM for 30 minutes and assayed for phosphorylation. In experiments shown in A–I, sequential treatments were performed without intermediate washing steps. Each compound was used at the same concentration in all experiments. Data are shown as means ± SD. **P < 0.001, ***P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (A and C–H).
Human Edil3 Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/Human+EDIL3+DuoSet+ELISA/pm38263289-326-11-15
Average 94 stars, based on 1 article reviews
human edil3 duoset elisa - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
human del 1 protein  (R&D Systems)
93
R&D Systems human del 1 protein
(A) DEL1 mRNA expression determined by qPCR and DEL-1 protein levels determined by ELISA in control or GHSR siRNA-transfected HMVECs treated with ERM (10 μg/mL) or ghrelin (5 μg/mL) 3 hours (mRNA) or 6 hours (protein) (n = 6 culture sets/group). Data normalized against GAPDH mRNA are expressed as fold induction relative to ethanol (set as 1). (B) HMVECs, pretreated for 24 hours with control or GHSR siRNA (20 nM), were incubated with ERM and assayed for phosphorylation at indicated points. (C) After 1-hour pretreatment with AG490 (10 μM), LY294002 (20 μM), or SB203580 (10 μM), HMVECs were incubated 3 hours with ERM and assayed for DEL1 expression (n = 6 culture sets/group). Data normalized against GAPDH mRNA were expressed as fold induction relative to ethanol control (set as 1). (D) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid, pretreated 1 hour with inhibitors, and subsequently incubated 8 hours with ERM or control followed by luciferase assay. Data are presented as fold change relative to ethanol control, set as 1 (n = 6 culture sets/group). (E) HMVECs, pretreated as above with inhibitors, were incubated 4 hours with ERM and subjected to ChIP analysis of C/EBPβ occupancy at the <t>EDIL3</t> promoter (n = 4 culture sets/group). (F) After 30-minute pretreatment with ERM or RvD1 (100 nM), HMVECs were stimulated (3 hours), or not, with IL-17 (5 ng/mL). DEL1 mRNA expression was assayed and presented as above (n = 6 HMVEC culture sets/group). (G) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid and pretreated with inhibitors. After 1 hour, the cells were treated with ERM, RvD1, or control for 30 minutes, followed by 8-hour stimulation with IL-17 and luciferase activity assay (n = 6 culture sets/group). Data are presented as fold change relative to ethanol (set as 1). (H) After 1-hour pretreatment with inhibitors, HMVECs were treated with ERM, RvD1, or ethanol for 30 minutes, followed by 4-hour stimulation with IL-17. Chromatin was immunoprecipitated with anti–C/EBPβ IgG and subjected to qPCR of the DEL1 promoter. Nonimmunoprecipitated cell extracts served as input samples. (I) After 1-hour pretreatment with inhibitors, HMVECs were incubated with RvD1 or ERM for 30 minutes and assayed for phosphorylation. In experiments shown in A–I, sequential treatments were performed without intermediate washing steps. Each compound was used at the same concentration in all experiments. Data are shown as means ± SD. **P < 0.001, ***P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (A and C–H).
Human Del 1 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/Recombinant+Human+EDIL3+Protein%2C+CF/pmc07455085-467-2-28
Average 93 stars, based on 1 article reviews
human del 1 protein - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
gene exp edil3 hs00174781 m1  (Thermo Fisher)
92
Thermo Fisher gene exp edil3 hs00174781 m1
(A) DEL1 mRNA expression determined by qPCR and DEL-1 protein levels determined by ELISA in control or GHSR siRNA-transfected HMVECs treated with ERM (10 μg/mL) or ghrelin (5 μg/mL) 3 hours (mRNA) or 6 hours (protein) (n = 6 culture sets/group). Data normalized against GAPDH mRNA are expressed as fold induction relative to ethanol (set as 1). (B) HMVECs, pretreated for 24 hours with control or GHSR siRNA (20 nM), were incubated with ERM and assayed for phosphorylation at indicated points. (C) After 1-hour pretreatment with AG490 (10 μM), LY294002 (20 μM), or SB203580 (10 μM), HMVECs were incubated 3 hours with ERM and assayed for DEL1 expression (n = 6 culture sets/group). Data normalized against GAPDH mRNA were expressed as fold induction relative to ethanol control (set as 1). (D) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid, pretreated 1 hour with inhibitors, and subsequently incubated 8 hours with ERM or control followed by luciferase assay. Data are presented as fold change relative to ethanol control, set as 1 (n = 6 culture sets/group). (E) HMVECs, pretreated as above with inhibitors, were incubated 4 hours with ERM and subjected to ChIP analysis of C/EBPβ occupancy at the <t>EDIL3</t> promoter (n = 4 culture sets/group). (F) After 30-minute pretreatment with ERM or RvD1 (100 nM), HMVECs were stimulated (3 hours), or not, with IL-17 (5 ng/mL). DEL1 mRNA expression was assayed and presented as above (n = 6 HMVEC culture sets/group). (G) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid and pretreated with inhibitors. After 1 hour, the cells were treated with ERM, RvD1, or control for 30 minutes, followed by 8-hour stimulation with IL-17 and luciferase activity assay (n = 6 culture sets/group). Data are presented as fold change relative to ethanol (set as 1). (H) After 1-hour pretreatment with inhibitors, HMVECs were treated with ERM, RvD1, or ethanol for 30 minutes, followed by 4-hour stimulation with IL-17. Chromatin was immunoprecipitated with anti–C/EBPβ IgG and subjected to qPCR of the DEL1 promoter. Nonimmunoprecipitated cell extracts served as input samples. (I) After 1-hour pretreatment with inhibitors, HMVECs were incubated with RvD1 or ERM for 30 minutes and assayed for phosphorylation. In experiments shown in A–I, sequential treatments were performed without intermediate washing steps. Each compound was used at the same concentration in all experiments. Data are shown as means ± SD. **P < 0.001, ***P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (A and C–H).
Gene Exp Edil3 Hs00174781 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/Gene+Exp%2E+EDIL3%2C+Hs00174781_m1/10__1253_slash_circj__cj___16___0808-77-16-4
Average 92 stars, based on 1 article reviews
gene exp edil3 hs00174781 m1 - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
recombinant human del 1 protein 6046 ed  (R&D Systems)
94
R&D Systems recombinant human del 1 protein 6046 ed
(A) DEL1 mRNA expression determined by qPCR and DEL-1 protein levels determined by ELISA in control or GHSR siRNA-transfected HMVECs treated with ERM (10 μg/mL) or ghrelin (5 μg/mL) 3 hours (mRNA) or 6 hours (protein) (n = 6 culture sets/group). Data normalized against GAPDH mRNA are expressed as fold induction relative to ethanol (set as 1). (B) HMVECs, pretreated for 24 hours with control or GHSR siRNA (20 nM), were incubated with ERM and assayed for phosphorylation at indicated points. (C) After 1-hour pretreatment with AG490 (10 μM), LY294002 (20 μM), or SB203580 (10 μM), HMVECs were incubated 3 hours with ERM and assayed for DEL1 expression (n = 6 culture sets/group). Data normalized against GAPDH mRNA were expressed as fold induction relative to ethanol control (set as 1). (D) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid, pretreated 1 hour with inhibitors, and subsequently incubated 8 hours with ERM or control followed by luciferase assay. Data are presented as fold change relative to ethanol control, set as 1 (n = 6 culture sets/group). (E) HMVECs, pretreated as above with inhibitors, were incubated 4 hours with ERM and subjected to ChIP analysis of C/EBPβ occupancy at the <t>EDIL3</t> promoter (n = 4 culture sets/group). (F) After 30-minute pretreatment with ERM or RvD1 (100 nM), HMVECs were stimulated (3 hours), or not, with IL-17 (5 ng/mL). DEL1 mRNA expression was assayed and presented as above (n = 6 HMVEC culture sets/group). (G) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid and pretreated with inhibitors. After 1 hour, the cells were treated with ERM, RvD1, or control for 30 minutes, followed by 8-hour stimulation with IL-17 and luciferase activity assay (n = 6 culture sets/group). Data are presented as fold change relative to ethanol (set as 1). (H) After 1-hour pretreatment with inhibitors, HMVECs were treated with ERM, RvD1, or ethanol for 30 minutes, followed by 4-hour stimulation with IL-17. Chromatin was immunoprecipitated with anti–C/EBPβ IgG and subjected to qPCR of the DEL1 promoter. Nonimmunoprecipitated cell extracts served as input samples. (I) After 1-hour pretreatment with inhibitors, HMVECs were incubated with RvD1 or ERM for 30 minutes and assayed for phosphorylation. In experiments shown in A–I, sequential treatments were performed without intermediate washing steps. Each compound was used at the same concentration in all experiments. Data are shown as means ± SD. **P < 0.001, ***P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (A and C–H).
Recombinant Human Del 1 Protein 6046 Ed, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/Recombinant+Human+EDIL3+Protein%2C+CF/bio_rxiv__2022__04__04__487024-81-8-13
Average 94 stars, based on 1 article reviews
recombinant human del 1 protein 6046 ed - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
mouse edil3 elisa kit  (Cusabio)
93
Cusabio mouse edil3 elisa kit
(A) DEL1 mRNA expression determined by qPCR and DEL-1 protein levels determined by ELISA in control or GHSR siRNA-transfected HMVECs treated with ERM (10 μg/mL) or ghrelin (5 μg/mL) 3 hours (mRNA) or 6 hours (protein) (n = 6 culture sets/group). Data normalized against GAPDH mRNA are expressed as fold induction relative to ethanol (set as 1). (B) HMVECs, pretreated for 24 hours with control or GHSR siRNA (20 nM), were incubated with ERM and assayed for phosphorylation at indicated points. (C) After 1-hour pretreatment with AG490 (10 μM), LY294002 (20 μM), or SB203580 (10 μM), HMVECs were incubated 3 hours with ERM and assayed for DEL1 expression (n = 6 culture sets/group). Data normalized against GAPDH mRNA were expressed as fold induction relative to ethanol control (set as 1). (D) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid, pretreated 1 hour with inhibitors, and subsequently incubated 8 hours with ERM or control followed by luciferase assay. Data are presented as fold change relative to ethanol control, set as 1 (n = 6 culture sets/group). (E) HMVECs, pretreated as above with inhibitors, were incubated 4 hours with ERM and subjected to ChIP analysis of C/EBPβ occupancy at the <t>EDIL3</t> promoter (n = 4 culture sets/group). (F) After 30-minute pretreatment with ERM or RvD1 (100 nM), HMVECs were stimulated (3 hours), or not, with IL-17 (5 ng/mL). DEL1 mRNA expression was assayed and presented as above (n = 6 HMVEC culture sets/group). (G) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid and pretreated with inhibitors. After 1 hour, the cells were treated with ERM, RvD1, or control for 30 minutes, followed by 8-hour stimulation with IL-17 and luciferase activity assay (n = 6 culture sets/group). Data are presented as fold change relative to ethanol (set as 1). (H) After 1-hour pretreatment with inhibitors, HMVECs were treated with ERM, RvD1, or ethanol for 30 minutes, followed by 4-hour stimulation with IL-17. Chromatin was immunoprecipitated with anti–C/EBPβ IgG and subjected to qPCR of the DEL1 promoter. Nonimmunoprecipitated cell extracts served as input samples. (I) After 1-hour pretreatment with inhibitors, HMVECs were incubated with RvD1 or ERM for 30 minutes and assayed for phosphorylation. In experiments shown in A–I, sequential treatments were performed without intermediate washing steps. Each compound was used at the same concentration in all experiments. Data are shown as means ± SD. **P < 0.001, ***P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (A and C–H).
Mouse Edil3 Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/EDIL3/pmc10805706-333-11-15
Average 93 stars, based on 1 article reviews
mouse edil3 elisa kit - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
human edil3 antibody  (R&D Systems)
93
R&D Systems human edil3 antibody
Primary fibroblast-derived EXOs display an activation status dependent protein cargo. The established fibroblast cell lines were subjected to cellular protein isolation after 48 h incubation of equal cell numbers in normal growth medium. EXOs were isolated using combined differential centrifugation and ultrafiltration approach following 48 h of fibroblast incubation in starvation medium. Exosomal protein was isolated in biological triplicates and subjected to Mass Spectrometry. Statistical Analysis was performed in Perseus. ( A ) Immunoblot analysis of vimentin (VIM), α-smooth-muscle actin (αSMA), fibroblast activation protein α (FAPα), caveolin 1 (CAV1), cluster of differentiation 90 (CD90)/Thy1 and fibroblast-specific protein 1 (FSP1) in primary fibroblasts, including GAPDH as loading control. ( B ) Particle size distribution in the isolated EXOs (mean of n = 4–10) as measured by nanoparticle tracking analysis (NTA) using ZetaView ® . ( C ) Representative transmission electron microscopy (TEM) image of fibroblast-derived EXOs. ( D ) Immunoblot analysis of EXO markers CD9, CD63, CD81, Flotillin 1 and Tumor susceptibility 101 (TSG101), including calreticulin as negative control. ( E ) Heat map of mass spectrometry data illustrating significantly deregulated vesicular proteins. Proteins with more than 4 undefined values in total or more than 3 undefined values in the NF/CAF subgroups are excluded. Paired t test: q < 0.05, diff. > |1.0|. LFQ: label-free quantification; nda: no data acquired. ( F ) Immunoblot analysis of quiescin sulfhydryl oxidase 1 (QSOX1), actinin α4 (ACTN4), thrombospondin 1 (THBS1) and EGF-like repeats and discoidin domains 3 <t>(EDIL3)</t> in EXOs. ( G ) Immunoblot analysis of QSOX1, ACTN4, THBS1 and EDIL3 in primary fibroblasts whole cell lysate, including GAPDH as loading control. The images of uncropped western blot figures are shown in .
Human Edil3 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/Human+EDIL3+Antibody/pmc08002505-65-82-86
Average 93 stars, based on 1 article reviews
human edil3 antibody - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
human edil3  (OriGene)
90
OriGene human edil3
<t>EDIL3</t> is significantly up-regulated in HCC and PVTT compared with normal liver (NL) and cirrhotic livers (CL) and is closely related to the prognosis of HCC. A , The transcriptional level of EDIL3 is measured via qRT-PCR in 5 NLs, 10 CLs and 49 HCCs. The relative mRNA level is normalized to β-actin and is presented as Δ–ΔCq. The mRNA of EDIL3 in HCC is significantly higher than both NL and CL; B , The protein level of EDIL3 in NL, CL, HCC and PVTT was examined by western blot with β-actin as a loading control. The EDIL3/β-actin densitometry is performed and shown as density value below. EDIL3 is mildly expressed In NL and CL while significantly elevated in HCC and PVTT; C , Representative pictures demonstrating EDIL3 staining in different liver samples including NL, CL, HCC, PVTT and microscopic thrombi by IHC. Scale bars, 50 μm or 150 μm; Arrow heads indicate that high EDIL3 expression is largely localized to cancer cells. D , Confocal microscopic observation of immunofluorescence staining of CD31 (green), an endothelium marker, and EDIL3 (red) in HCC samples show EDIL3 is not only localized with endothelium, but also widely and diffusively located in cancer cells clusters. White arrows indicates the endothelium; Grey arrows indicates the cancer cell cluster. E , Kaplan-Meier analysis of overall survival between EDIL3-negative or moderately positive patients and highly positive patients shows a significant survival advantage in EDIL3 low express group. **: P < 0.01.
Human Edil3, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/EDIL3+(NM_005711)+Human+Tagged+ORF+Clone/pmc04200221-246-0-3
Average 90 stars, based on 1 article reviews
human edil3 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human recombinant edil3 (del1)  (Abnova)
90
Abnova human recombinant edil3 (del1)
KEY RESOURCES TABLE
Human Recombinant Edil3 (Del1), supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/edil3+del1++h00010085+p01+/pmc07111494-55-0-5
Average 90 stars, based on 1 article reviews
human recombinant edil3 (del1) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
gene exp edil3 hs00964112 m1  (Thermo Fisher)
93
Thermo Fisher gene exp edil3 hs00964112 m1
KEY RESOURCES TABLE
Gene Exp Edil3 Hs00964112 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/Gene+Exp%2E+EDIL3%2C+Hs00964112_m1/pmc10797555__mmc1-3-44-45
Average 93 stars, based on 1 article reviews
gene exp edil3 hs00964112 m1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
novus biologicals nbp1 28632  (Novus Biologicals)
93
Novus Biologicals novus biologicals nbp1 28632
KEY RESOURCES TABLE
Novus Biologicals Nbp1 28632, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdna+for+human+edil3+(encoding+del-1)/EDIL3%2FDEL1+Antibody+-+BSA+Free/bio_rxiv__348177-113-20-20
Average 93 stars, based on 1 article reviews
novus biologicals nbp1 28632 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


(A) DEL1 mRNA expression determined by qPCR and DEL-1 protein levels determined by ELISA in control or GHSR siRNA-transfected HMVECs treated with ERM (10 μg/mL) or ghrelin (5 μg/mL) 3 hours (mRNA) or 6 hours (protein) (n = 6 culture sets/group). Data normalized against GAPDH mRNA are expressed as fold induction relative to ethanol (set as 1). (B) HMVECs, pretreated for 24 hours with control or GHSR siRNA (20 nM), were incubated with ERM and assayed for phosphorylation at indicated points. (C) After 1-hour pretreatment with AG490 (10 μM), LY294002 (20 μM), or SB203580 (10 μM), HMVECs were incubated 3 hours with ERM and assayed for DEL1 expression (n = 6 culture sets/group). Data normalized against GAPDH mRNA were expressed as fold induction relative to ethanol control (set as 1). (D) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid, pretreated 1 hour with inhibitors, and subsequently incubated 8 hours with ERM or control followed by luciferase assay. Data are presented as fold change relative to ethanol control, set as 1 (n = 6 culture sets/group). (E) HMVECs, pretreated as above with inhibitors, were incubated 4 hours with ERM and subjected to ChIP analysis of C/EBPβ occupancy at the EDIL3 promoter (n = 4 culture sets/group). (F) After 30-minute pretreatment with ERM or RvD1 (100 nM), HMVECs were stimulated (3 hours), or not, with IL-17 (5 ng/mL). DEL1 mRNA expression was assayed and presented as above (n = 6 HMVEC culture sets/group). (G) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid and pretreated with inhibitors. After 1 hour, the cells were treated with ERM, RvD1, or control for 30 minutes, followed by 8-hour stimulation with IL-17 and luciferase activity assay (n = 6 culture sets/group). Data are presented as fold change relative to ethanol (set as 1). (H) After 1-hour pretreatment with inhibitors, HMVECs were treated with ERM, RvD1, or ethanol for 30 minutes, followed by 4-hour stimulation with IL-17. Chromatin was immunoprecipitated with anti–C/EBPβ IgG and subjected to qPCR of the DEL1 promoter. Nonimmunoprecipitated cell extracts served as input samples. (I) After 1-hour pretreatment with inhibitors, HMVECs were incubated with RvD1 or ERM for 30 minutes and assayed for phosphorylation. In experiments shown in A–I, sequential treatments were performed without intermediate washing steps. Each compound was used at the same concentration in all experiments. Data are shown as means ± SD. **P < 0.001, ***P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (A and C–H).

Journal: JCI Insight

Article Title: Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1

doi: 10.1172/jci.insight.136706

Figure Lengend Snippet: (A) DEL1 mRNA expression determined by qPCR and DEL-1 protein levels determined by ELISA in control or GHSR siRNA-transfected HMVECs treated with ERM (10 μg/mL) or ghrelin (5 μg/mL) 3 hours (mRNA) or 6 hours (protein) (n = 6 culture sets/group). Data normalized against GAPDH mRNA are expressed as fold induction relative to ethanol (set as 1). (B) HMVECs, pretreated for 24 hours with control or GHSR siRNA (20 nM), were incubated with ERM and assayed for phosphorylation at indicated points. (C) After 1-hour pretreatment with AG490 (10 μM), LY294002 (20 μM), or SB203580 (10 μM), HMVECs were incubated 3 hours with ERM and assayed for DEL1 expression (n = 6 culture sets/group). Data normalized against GAPDH mRNA were expressed as fold induction relative to ethanol control (set as 1). (D) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid, pretreated 1 hour with inhibitors, and subsequently incubated 8 hours with ERM or control followed by luciferase assay. Data are presented as fold change relative to ethanol control, set as 1 (n = 6 culture sets/group). (E) HMVECs, pretreated as above with inhibitors, were incubated 4 hours with ERM and subjected to ChIP analysis of C/EBPβ occupancy at the EDIL3 promoter (n = 4 culture sets/group). (F) After 30-minute pretreatment with ERM or RvD1 (100 nM), HMVECs were stimulated (3 hours), or not, with IL-17 (5 ng/mL). DEL1 mRNA expression was assayed and presented as above (n = 6 HMVEC culture sets/group). (G) HMVECs were transiently transfected with hEDIL3-promoter-Luc reporter plasmid and pretreated with inhibitors. After 1 hour, the cells were treated with ERM, RvD1, or control for 30 minutes, followed by 8-hour stimulation with IL-17 and luciferase activity assay (n = 6 culture sets/group). Data are presented as fold change relative to ethanol (set as 1). (H) After 1-hour pretreatment with inhibitors, HMVECs were treated with ERM, RvD1, or ethanol for 30 minutes, followed by 4-hour stimulation with IL-17. Chromatin was immunoprecipitated with anti–C/EBPβ IgG and subjected to qPCR of the DEL1 promoter. Nonimmunoprecipitated cell extracts served as input samples. (I) After 1-hour pretreatment with inhibitors, HMVECs were incubated with RvD1 or ERM for 30 minutes and assayed for phosphorylation. In experiments shown in A–I, sequential treatments were performed without intermediate washing steps. Each compound was used at the same concentration in all experiments. Data are shown as means ± SD. **P < 0.001, ***P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (A and C–H).

Article Snippet: TaqMan probes, sense primers, and antisense primers for the expression of a housekeeping gene ( GAPDH ; Mm99999915_g1, Gapdh ; Hs02786624_g1), as well as investigated genes Edil3 ( Del1 ) ( Del1 ; Mm01291247_m1, DEL1 ; Hs00964112_m1), Il6 (Mm00446190_m1), Il1b (Mm00434228_m1), Tnf (Mm00443258_m1), Il10 (Mm01288386_m1), and Il17a (Mm00439618_m1), were purchased from Thermo Fisher Scientific.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Control, Transfection, Incubation, Phospho-proteomics, Plasmid Preparation, Luciferase, Activity Assay, Immunoprecipitation, Concentration Assay

Primary fibroblast-derived EXOs display an activation status dependent protein cargo. The established fibroblast cell lines were subjected to cellular protein isolation after 48 h incubation of equal cell numbers in normal growth medium. EXOs were isolated using combined differential centrifugation and ultrafiltration approach following 48 h of fibroblast incubation in starvation medium. Exosomal protein was isolated in biological triplicates and subjected to Mass Spectrometry. Statistical Analysis was performed in Perseus. ( A ) Immunoblot analysis of vimentin (VIM), α-smooth-muscle actin (αSMA), fibroblast activation protein α (FAPα), caveolin 1 (CAV1), cluster of differentiation 90 (CD90)/Thy1 and fibroblast-specific protein 1 (FSP1) in primary fibroblasts, including GAPDH as loading control. ( B ) Particle size distribution in the isolated EXOs (mean of n = 4–10) as measured by nanoparticle tracking analysis (NTA) using ZetaView ® . ( C ) Representative transmission electron microscopy (TEM) image of fibroblast-derived EXOs. ( D ) Immunoblot analysis of EXO markers CD9, CD63, CD81, Flotillin 1 and Tumor susceptibility 101 (TSG101), including calreticulin as negative control. ( E ) Heat map of mass spectrometry data illustrating significantly deregulated vesicular proteins. Proteins with more than 4 undefined values in total or more than 3 undefined values in the NF/CAF subgroups are excluded. Paired t test: q < 0.05, diff. > |1.0|. LFQ: label-free quantification; nda: no data acquired. ( F ) Immunoblot analysis of quiescin sulfhydryl oxidase 1 (QSOX1), actinin α4 (ACTN4), thrombospondin 1 (THBS1) and EGF-like repeats and discoidin domains 3 (EDIL3) in EXOs. ( G ) Immunoblot analysis of QSOX1, ACTN4, THBS1 and EDIL3 in primary fibroblasts whole cell lysate, including GAPDH as loading control. The images of uncropped western blot figures are shown in .

Journal: Cancers

Article Title: Proteomic Analyses of Fibroblast- and Serum-Derived Exosomes Identify QSOX1 as a Marker for Non-invasive Detection of Colorectal Cancer

doi: 10.3390/cancers13061351

Figure Lengend Snippet: Primary fibroblast-derived EXOs display an activation status dependent protein cargo. The established fibroblast cell lines were subjected to cellular protein isolation after 48 h incubation of equal cell numbers in normal growth medium. EXOs were isolated using combined differential centrifugation and ultrafiltration approach following 48 h of fibroblast incubation in starvation medium. Exosomal protein was isolated in biological triplicates and subjected to Mass Spectrometry. Statistical Analysis was performed in Perseus. ( A ) Immunoblot analysis of vimentin (VIM), α-smooth-muscle actin (αSMA), fibroblast activation protein α (FAPα), caveolin 1 (CAV1), cluster of differentiation 90 (CD90)/Thy1 and fibroblast-specific protein 1 (FSP1) in primary fibroblasts, including GAPDH as loading control. ( B ) Particle size distribution in the isolated EXOs (mean of n = 4–10) as measured by nanoparticle tracking analysis (NTA) using ZetaView ® . ( C ) Representative transmission electron microscopy (TEM) image of fibroblast-derived EXOs. ( D ) Immunoblot analysis of EXO markers CD9, CD63, CD81, Flotillin 1 and Tumor susceptibility 101 (TSG101), including calreticulin as negative control. ( E ) Heat map of mass spectrometry data illustrating significantly deregulated vesicular proteins. Proteins with more than 4 undefined values in total or more than 3 undefined values in the NF/CAF subgroups are excluded. Paired t test: q < 0.05, diff. > |1.0|. LFQ: label-free quantification; nda: no data acquired. ( F ) Immunoblot analysis of quiescin sulfhydryl oxidase 1 (QSOX1), actinin α4 (ACTN4), thrombospondin 1 (THBS1) and EGF-like repeats and discoidin domains 3 (EDIL3) in EXOs. ( G ) Immunoblot analysis of QSOX1, ACTN4, THBS1 and EDIL3 in primary fibroblasts whole cell lysate, including GAPDH as loading control. The images of uncropped western blot figures are shown in .

Article Snippet: For the detection of proteins of interest, the following primary antibodies were used: recombinant anti-CD9 antibody [EPR2949] (ab92726, Abcam, 1:200), anti-CD63 antibody (ab68418, Abcam, 1:500), CD81 antibody (NBP2-20564, Novus Biologicals, Centennial, CO, USA, 1:400), anti-TSG101 antibody [4A10] (ab83, Abcam, 1:500), Flotillin-1 antibody (3253, Cell Signaling Technology, 1:500), calreticulin antibody (2891, Cell Signaling Technology, 1:1000), recombinant anti-Quiescin Q6 antibody [EPR21866] (ab235444, Abcam, 1:1000), α-actinin 4 (D7U5A) rabbit mAB (15145, Cell Signaling Technology, 1:1000), thrombospondin-1 (D7E5F) rabbit mAb (37879, Cell Signaling Technology, 1:200) and human EDIL3 antibody (MAB6046, R&D Systems, 1:500).

Techniques: Derivative Assay, Activation Assay, Isolation, Incubation, Centrifugation, Mass Spectrometry, Western Blot, Control, Transmission Assay, Electron Microscopy, Negative Control, Quantitative Proteomics

Selected primary fibroblast activation status dependent EXO markers display specificity to blood EXOs in matched CRC patient plasma. ( A ) Particle size distribution of patient-matched plasma EXOs (pEXO) in comparison to whole plasma (wP) and EXO-depleted plasma (edP) as measured by NTA. ( B ) Immunoblot analysis of quiescin sulfhydryl oxidase 1 (QSOX1), thrombospondin 1 (THBS1), EGF-like repeats and discoidin domains 3 (EDIL3), the EXO markers CD9, CD63 and Flotillin 1, including calreticulin as negative control, and albumin in wP, pEXO and edP protein lysates. ( C ) Graphical analysis of immunoblots shown in (B) using ImageJ, comparing signal strength to pEXO mix. Unpaired t -test: * p < 0.05, ** p < 0.01, *** p < 0.001.

Journal: Cancers

Article Title: Proteomic Analyses of Fibroblast- and Serum-Derived Exosomes Identify QSOX1 as a Marker for Non-invasive Detection of Colorectal Cancer

doi: 10.3390/cancers13061351

Figure Lengend Snippet: Selected primary fibroblast activation status dependent EXO markers display specificity to blood EXOs in matched CRC patient plasma. ( A ) Particle size distribution of patient-matched plasma EXOs (pEXO) in comparison to whole plasma (wP) and EXO-depleted plasma (edP) as measured by NTA. ( B ) Immunoblot analysis of quiescin sulfhydryl oxidase 1 (QSOX1), thrombospondin 1 (THBS1), EGF-like repeats and discoidin domains 3 (EDIL3), the EXO markers CD9, CD63 and Flotillin 1, including calreticulin as negative control, and albumin in wP, pEXO and edP protein lysates. ( C ) Graphical analysis of immunoblots shown in (B) using ImageJ, comparing signal strength to pEXO mix. Unpaired t -test: * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: For the detection of proteins of interest, the following primary antibodies were used: recombinant anti-CD9 antibody [EPR2949] (ab92726, Abcam, 1:200), anti-CD63 antibody (ab68418, Abcam, 1:500), CD81 antibody (NBP2-20564, Novus Biologicals, Centennial, CO, USA, 1:400), anti-TSG101 antibody [4A10] (ab83, Abcam, 1:500), Flotillin-1 antibody (3253, Cell Signaling Technology, 1:500), calreticulin antibody (2891, Cell Signaling Technology, 1:1000), recombinant anti-Quiescin Q6 antibody [EPR21866] (ab235444, Abcam, 1:1000), α-actinin 4 (D7U5A) rabbit mAB (15145, Cell Signaling Technology, 1:1000), thrombospondin-1 (D7E5F) rabbit mAb (37879, Cell Signaling Technology, 1:200) and human EDIL3 antibody (MAB6046, R&D Systems, 1:500).

Techniques: Activation Assay, Clinical Proteomics, Comparison, Western Blot, Negative Control

In vivo marker expression in patient-matched healthy and malignant colon tissue. ( A ) Representative images of paraffin embedded tissue slides of healthy (hC) and malignant (CRC) colon tissue derived from patients 1–3, hematoxylin and eosin (H&E) or immunohistochemically stained for the proteins quiescin sulfhydryl oxidase 1 (QSOX1), thrombospondin 1 (THBS1), EGF-like repeats and discoidin domains 3 (EDIL3), α-smooth-muscle actin (αSMA) and IgG control (Ctrl.). Scale bars equal 250 µm. ( B ) Graphical IHC staining analysis performed in QuPath. From each patient and tissue, a minimum of three representative areas were subjected to graphical and statistical analysis. Mann-Whitney-U test: * p < 0.05, ** p < 0.01. ns = not significant.

Journal: Cancers

Article Title: Proteomic Analyses of Fibroblast- and Serum-Derived Exosomes Identify QSOX1 as a Marker for Non-invasive Detection of Colorectal Cancer

doi: 10.3390/cancers13061351

Figure Lengend Snippet: In vivo marker expression in patient-matched healthy and malignant colon tissue. ( A ) Representative images of paraffin embedded tissue slides of healthy (hC) and malignant (CRC) colon tissue derived from patients 1–3, hematoxylin and eosin (H&E) or immunohistochemically stained for the proteins quiescin sulfhydryl oxidase 1 (QSOX1), thrombospondin 1 (THBS1), EGF-like repeats and discoidin domains 3 (EDIL3), α-smooth-muscle actin (αSMA) and IgG control (Ctrl.). Scale bars equal 250 µm. ( B ) Graphical IHC staining analysis performed in QuPath. From each patient and tissue, a minimum of three representative areas were subjected to graphical and statistical analysis. Mann-Whitney-U test: * p < 0.05, ** p < 0.01. ns = not significant.

Article Snippet: For the detection of proteins of interest, the following primary antibodies were used: recombinant anti-CD9 antibody [EPR2949] (ab92726, Abcam, 1:200), anti-CD63 antibody (ab68418, Abcam, 1:500), CD81 antibody (NBP2-20564, Novus Biologicals, Centennial, CO, USA, 1:400), anti-TSG101 antibody [4A10] (ab83, Abcam, 1:500), Flotillin-1 antibody (3253, Cell Signaling Technology, 1:500), calreticulin antibody (2891, Cell Signaling Technology, 1:1000), recombinant anti-Quiescin Q6 antibody [EPR21866] (ab235444, Abcam, 1:1000), α-actinin 4 (D7U5A) rabbit mAB (15145, Cell Signaling Technology, 1:1000), thrombospondin-1 (D7E5F) rabbit mAb (37879, Cell Signaling Technology, 1:200) and human EDIL3 antibody (MAB6046, R&D Systems, 1:500).

Techniques: In Vivo, Marker, Expressing, Derivative Assay, Staining, Control, Immunohistochemistry, MANN-WHITNEY

Exosomal fibroblast activity marker validation in an independent validation cohort. Twenty additional fibroblast cell lines derived from 10 CRC patients were subjected to cellular protein and EXO isolation. Exosomal protein was isolated and subjected to immunoblot. ( A ) Immunoblot analysis of quiescin sulfhydryl oxidase 1 (QSOX1), thrombospondin 1 (THBS1), EGF-like repeats and discoidin domains 3 (EDIL3), in primary fibroblasts-derived EXOs. ( B ) Immunoblot analysis of QSOX1, THBS1 and EDIL3 in primary fibroblasts whole cell lysate, including GAPDH as loading control. ( C ) Graphical analysis of EXO protein immunoblots shown in ( A ) using ImageJ, relative to GAPDH. Mann-Whitney-U test: * p < 0.05. ( D ) Graphical analysis of cellular protein immunoblots shown in ( B ) using ImageJ, relative to GAPDH. Mann-Whitney-U test: * p < 0.05, *** p < 0.001. ns = not significant.

Journal: Cancers

Article Title: Proteomic Analyses of Fibroblast- and Serum-Derived Exosomes Identify QSOX1 as a Marker for Non-invasive Detection of Colorectal Cancer

doi: 10.3390/cancers13061351

Figure Lengend Snippet: Exosomal fibroblast activity marker validation in an independent validation cohort. Twenty additional fibroblast cell lines derived from 10 CRC patients were subjected to cellular protein and EXO isolation. Exosomal protein was isolated and subjected to immunoblot. ( A ) Immunoblot analysis of quiescin sulfhydryl oxidase 1 (QSOX1), thrombospondin 1 (THBS1), EGF-like repeats and discoidin domains 3 (EDIL3), in primary fibroblasts-derived EXOs. ( B ) Immunoblot analysis of QSOX1, THBS1 and EDIL3 in primary fibroblasts whole cell lysate, including GAPDH as loading control. ( C ) Graphical analysis of EXO protein immunoblots shown in ( A ) using ImageJ, relative to GAPDH. Mann-Whitney-U test: * p < 0.05. ( D ) Graphical analysis of cellular protein immunoblots shown in ( B ) using ImageJ, relative to GAPDH. Mann-Whitney-U test: * p < 0.05, *** p < 0.001. ns = not significant.

Article Snippet: For the detection of proteins of interest, the following primary antibodies were used: recombinant anti-CD9 antibody [EPR2949] (ab92726, Abcam, 1:200), anti-CD63 antibody (ab68418, Abcam, 1:500), CD81 antibody (NBP2-20564, Novus Biologicals, Centennial, CO, USA, 1:400), anti-TSG101 antibody [4A10] (ab83, Abcam, 1:500), Flotillin-1 antibody (3253, Cell Signaling Technology, 1:500), calreticulin antibody (2891, Cell Signaling Technology, 1:1000), recombinant anti-Quiescin Q6 antibody [EPR21866] (ab235444, Abcam, 1:1000), α-actinin 4 (D7U5A) rabbit mAB (15145, Cell Signaling Technology, 1:1000), thrombospondin-1 (D7E5F) rabbit mAb (37879, Cell Signaling Technology, 1:200) and human EDIL3 antibody (MAB6046, R&D Systems, 1:500).

Techniques: Activity Assay, Marker, Biomarker Discovery, Derivative Assay, Isolation, Western Blot, Control, MANN-WHITNEY

EDIL3 is significantly up-regulated in HCC and PVTT compared with normal liver (NL) and cirrhotic livers (CL) and is closely related to the prognosis of HCC. A , The transcriptional level of EDIL3 is measured via qRT-PCR in 5 NLs, 10 CLs and 49 HCCs. The relative mRNA level is normalized to β-actin and is presented as Δ–ΔCq. The mRNA of EDIL3 in HCC is significantly higher than both NL and CL; B , The protein level of EDIL3 in NL, CL, HCC and PVTT was examined by western blot with β-actin as a loading control. The EDIL3/β-actin densitometry is performed and shown as density value below. EDIL3 is mildly expressed In NL and CL while significantly elevated in HCC and PVTT; C , Representative pictures demonstrating EDIL3 staining in different liver samples including NL, CL, HCC, PVTT and microscopic thrombi by IHC. Scale bars, 50 μm or 150 μm; Arrow heads indicate that high EDIL3 expression is largely localized to cancer cells. D , Confocal microscopic observation of immunofluorescence staining of CD31 (green), an endothelium marker, and EDIL3 (red) in HCC samples show EDIL3 is not only localized with endothelium, but also widely and diffusively located in cancer cells clusters. White arrows indicates the endothelium; Grey arrows indicates the cancer cell cluster. E , Kaplan-Meier analysis of overall survival between EDIL3-negative or moderately positive patients and highly positive patients shows a significant survival advantage in EDIL3 low express group. **: P < 0.01.

Journal: Molecular Cancer

Article Title: Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation

doi: 10.1186/1476-4598-13-226

Figure Lengend Snippet: EDIL3 is significantly up-regulated in HCC and PVTT compared with normal liver (NL) and cirrhotic livers (CL) and is closely related to the prognosis of HCC. A , The transcriptional level of EDIL3 is measured via qRT-PCR in 5 NLs, 10 CLs and 49 HCCs. The relative mRNA level is normalized to β-actin and is presented as Δ–ΔCq. The mRNA of EDIL3 in HCC is significantly higher than both NL and CL; B , The protein level of EDIL3 in NL, CL, HCC and PVTT was examined by western blot with β-actin as a loading control. The EDIL3/β-actin densitometry is performed and shown as density value below. EDIL3 is mildly expressed In NL and CL while significantly elevated in HCC and PVTT; C , Representative pictures demonstrating EDIL3 staining in different liver samples including NL, CL, HCC, PVTT and microscopic thrombi by IHC. Scale bars, 50 μm or 150 μm; Arrow heads indicate that high EDIL3 expression is largely localized to cancer cells. D , Confocal microscopic observation of immunofluorescence staining of CD31 (green), an endothelium marker, and EDIL3 (red) in HCC samples show EDIL3 is not only localized with endothelium, but also widely and diffusively located in cancer cells clusters. White arrows indicates the endothelium; Grey arrows indicates the cancer cell cluster. E , Kaplan-Meier analysis of overall survival between EDIL3-negative or moderately positive patients and highly positive patients shows a significant survival advantage in EDIL3 low express group. **: P < 0.01.

Article Snippet: Human EDIL3 (NM_005711 Origene) with the signal peptide truncated were cloned into the episomal expression vector pCEP-Pu-Strep II-tag (N-terminal) in-frame with the sequence of the BM-40 (SPARC/osteonectin) signal peptide downstream of the CMV promoter, which has been described elsewhere [ ].

Techniques: Quantitative RT-PCR, Western Blot, Control, Staining, Expressing, Immunofluorescence, Marker

EDIL3 exhibits a unique expression pattern in cell lines. A , detailed analysis of EDIL3 expression in mRNA level, cell lysates and CMs of 7 HCC and 2 non-HCC cell lines demonstrated an approximate correlation between mRNA and secreted EDIL3 in CMs, whereas EDIL3 in cell lysates exhibited almost same intensity. Notably, Huh-7 and CSQT-2 exhibited a much higher level of secreted EDIL3. B , ELISA assay testing the EDIL3 in CMs of 9 cell lines validates the secreted EDIL3 level is approximately correlated with mRNA level. C , Immunofluorescence staining of EDIL3, F-actin and DAPI in confocal microscope shows EDIL3 is localized within cells and at almost the same intensity in all the 9 cell lines under test, despite their varied mRNA level.

Journal: Molecular Cancer

Article Title: Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation

doi: 10.1186/1476-4598-13-226

Figure Lengend Snippet: EDIL3 exhibits a unique expression pattern in cell lines. A , detailed analysis of EDIL3 expression in mRNA level, cell lysates and CMs of 7 HCC and 2 non-HCC cell lines demonstrated an approximate correlation between mRNA and secreted EDIL3 in CMs, whereas EDIL3 in cell lysates exhibited almost same intensity. Notably, Huh-7 and CSQT-2 exhibited a much higher level of secreted EDIL3. B , ELISA assay testing the EDIL3 in CMs of 9 cell lines validates the secreted EDIL3 level is approximately correlated with mRNA level. C , Immunofluorescence staining of EDIL3, F-actin and DAPI in confocal microscope shows EDIL3 is localized within cells and at almost the same intensity in all the 9 cell lines under test, despite their varied mRNA level.

Article Snippet: Human EDIL3 (NM_005711 Origene) with the signal peptide truncated were cloned into the episomal expression vector pCEP-Pu-Strep II-tag (N-terminal) in-frame with the sequence of the BM-40 (SPARC/osteonectin) signal peptide downstream of the CMV promoter, which has been described elsewhere [ ].

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Microscopy

Treatment of EDIL3 contributes to anoikis resistance and anchorage-independent growth advantage in HCC. A , Different concentration of recombinant EDIL3 is used to treat SMMC-7721 suspended in poly-hema coated dishes. It sustains the viability of SMMC-7721 as demonstrated by caspase3WSt-8 assay in a time and dose dependent manner compared with control protein. B , Recombinant EDIL3 ameliorate the anoikis compared with control protein in SMMC-7721 as demonstrated by caspase3/7 intensity assay in a time and dose dependent manner. C-D , MHCC-97H is subjected to the assays same as SMMC-7721 and obtain consistent result. E , Administration of recombinant EDIL3 increases the anchorage-independent growth of SMMC-7721 and MHCC-97H cells in soft agar compared with control protein in a dose dependent manner. The assays last for 28 days. *: P < 0.05; **: P < 0.01.

Journal: Molecular Cancer

Article Title: Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation

doi: 10.1186/1476-4598-13-226

Figure Lengend Snippet: Treatment of EDIL3 contributes to anoikis resistance and anchorage-independent growth advantage in HCC. A , Different concentration of recombinant EDIL3 is used to treat SMMC-7721 suspended in poly-hema coated dishes. It sustains the viability of SMMC-7721 as demonstrated by caspase3WSt-8 assay in a time and dose dependent manner compared with control protein. B , Recombinant EDIL3 ameliorate the anoikis compared with control protein in SMMC-7721 as demonstrated by caspase3/7 intensity assay in a time and dose dependent manner. C-D , MHCC-97H is subjected to the assays same as SMMC-7721 and obtain consistent result. E , Administration of recombinant EDIL3 increases the anchorage-independent growth of SMMC-7721 and MHCC-97H cells in soft agar compared with control protein in a dose dependent manner. The assays last for 28 days. *: P < 0.05; **: P < 0.01.

Article Snippet: Human EDIL3 (NM_005711 Origene) with the signal peptide truncated were cloned into the episomal expression vector pCEP-Pu-Strep II-tag (N-terminal) in-frame with the sequence of the BM-40 (SPARC/osteonectin) signal peptide downstream of the CMV promoter, which has been described elsewhere [ ].

Techniques: Concentration Assay, Recombinant, Control

EDIL3 promotes HCC tumorigenesis in vivo. A total of 1.0 × 10 6 of EDIL3-overexpressing or control SMMC-7721 cells are subcutaneously implanted into the right flank of 5 nude mice of each groups. The mice were observed and tumors formed are measured every week and resected after 6 weeks. A , After 6 weeks, EDIL3-overexpressing group shows relatively larger tumors compare with control group. B , qRT-PCR of 5 tumors in each group demonstrates a significant elevation in mRNA level. C , Tumor growth curve reveals a shorter latency in the EDIL3-overexpressing group (2 weeks) vs. the control group (4 weeks) and tumors in the EDIL3-overexpressing group are significantly larger than control group from 2 nd week to 4 th week. D , IHC stain in the same region of the tumor confirms the overexpression of EDIL3 and suggests more active proliferation (PCNA) and lower apoptosis (tunel) upon EDIL3 overexpression. **: P < 0.01.

Journal: Molecular Cancer

Article Title: Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation

doi: 10.1186/1476-4598-13-226

Figure Lengend Snippet: EDIL3 promotes HCC tumorigenesis in vivo. A total of 1.0 × 10 6 of EDIL3-overexpressing or control SMMC-7721 cells are subcutaneously implanted into the right flank of 5 nude mice of each groups. The mice were observed and tumors formed are measured every week and resected after 6 weeks. A , After 6 weeks, EDIL3-overexpressing group shows relatively larger tumors compare with control group. B , qRT-PCR of 5 tumors in each group demonstrates a significant elevation in mRNA level. C , Tumor growth curve reveals a shorter latency in the EDIL3-overexpressing group (2 weeks) vs. the control group (4 weeks) and tumors in the EDIL3-overexpressing group are significantly larger than control group from 2 nd week to 4 th week. D , IHC stain in the same region of the tumor confirms the overexpression of EDIL3 and suggests more active proliferation (PCNA) and lower apoptosis (tunel) upon EDIL3 overexpression. **: P < 0.01.

Article Snippet: Human EDIL3 (NM_005711 Origene) with the signal peptide truncated were cloned into the episomal expression vector pCEP-Pu-Strep II-tag (N-terminal) in-frame with the sequence of the BM-40 (SPARC/osteonectin) signal peptide downstream of the CMV promoter, which has been described elsewhere [ ].

Techniques: In Vivo, Control, Quantitative RT-PCR, Staining, Over Expression, TUNEL Assay

Sustained activation of FAK-Src by EDIL3 through RGD recognition. A , Western blot and densimetric analysis suggests EDIL3 overexpression sustains the signal intensity of FAK-Src and results in higher AKT phosphorylation within suspended SMMC-7721 cells over 48 hours. The elevated 397 p-FAK, 416 p-Src and 473 p-AKT axis in overexpressing cells compare with control cells exists at most of the time points. B , Cilengitide (10 μM) reversed the activation of the FAK-Src-AKT axis induced by EDIL3. The signal intensity was examined after 24 h of suspension.

Journal: Molecular Cancer

Article Title: Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation

doi: 10.1186/1476-4598-13-226

Figure Lengend Snippet: Sustained activation of FAK-Src by EDIL3 through RGD recognition. A , Western blot and densimetric analysis suggests EDIL3 overexpression sustains the signal intensity of FAK-Src and results in higher AKT phosphorylation within suspended SMMC-7721 cells over 48 hours. The elevated 397 p-FAK, 416 p-Src and 473 p-AKT axis in overexpressing cells compare with control cells exists at most of the time points. B , Cilengitide (10 μM) reversed the activation of the FAK-Src-AKT axis induced by EDIL3. The signal intensity was examined after 24 h of suspension.

Article Snippet: Human EDIL3 (NM_005711 Origene) with the signal peptide truncated were cloned into the episomal expression vector pCEP-Pu-Strep II-tag (N-terminal) in-frame with the sequence of the BM-40 (SPARC/osteonectin) signal peptide downstream of the CMV promoter, which has been described elsewhere [ ].

Techniques: Activation Assay, Western Blot, Over Expression, Phospho-proteomics, Control, Suspension

Disrupting integrin-EDIL3 ligation deprives HCC of anoikis resistance induced by EDIL3 in SMMC-7721 and MHCC-LM3. A , Cilengitide (10 μM) reduces the WST-8 value and increased casepase3/7 of the EDIL3 overexpressing group back to levels of control group, suggesting a blockage of EDIL3’s effect. There was not any effect observed in the control group in WST-8 and caspase3/7 assay. Both the two cell lines show consistent results. B , when integrin αV was knocked down to a very low level in both cell lines by two siRNAs (Si2 and Si3), the alteration in WST-8 and casepase3/7 value of EDIL3-overexpressing cells compared with control cells disappear. Interestingly, the WST-8 value and casepase3/7 intensity results suggest the overall anoikis significantly declined upon integrin αV silencing in both siRNA knock-down groups compare with si-control group. **: P < 0.01.

Journal: Molecular Cancer

Article Title: Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation

doi: 10.1186/1476-4598-13-226

Figure Lengend Snippet: Disrupting integrin-EDIL3 ligation deprives HCC of anoikis resistance induced by EDIL3 in SMMC-7721 and MHCC-LM3. A , Cilengitide (10 μM) reduces the WST-8 value and increased casepase3/7 of the EDIL3 overexpressing group back to levels of control group, suggesting a blockage of EDIL3’s effect. There was not any effect observed in the control group in WST-8 and caspase3/7 assay. Both the two cell lines show consistent results. B , when integrin αV was knocked down to a very low level in both cell lines by two siRNAs (Si2 and Si3), the alteration in WST-8 and casepase3/7 value of EDIL3-overexpressing cells compared with control cells disappear. Interestingly, the WST-8 value and casepase3/7 intensity results suggest the overall anoikis significantly declined upon integrin αV silencing in both siRNA knock-down groups compare with si-control group. **: P < 0.01.

Article Snippet: Human EDIL3 (NM_005711 Origene) with the signal peptide truncated were cloned into the episomal expression vector pCEP-Pu-Strep II-tag (N-terminal) in-frame with the sequence of the BM-40 (SPARC/osteonectin) signal peptide downstream of the CMV promoter, which has been described elsewhere [ ].

Techniques: Ligation, Control, Knockdown

Correlation between EDIL3 and key clinicopathological parameters

Journal: Molecular Cancer

Article Title: Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation

doi: 10.1186/1476-4598-13-226

Figure Lengend Snippet: Correlation between EDIL3 and key clinicopathological parameters

Article Snippet: Human EDIL3 (NM_005711 Origene) with the signal peptide truncated were cloned into the episomal expression vector pCEP-Pu-Strep II-tag (N-terminal) in-frame with the sequence of the BM-40 (SPARC/osteonectin) signal peptide downstream of the CMV promoter, which has been described elsewhere [ ].

Techniques:

KEY RESOURCES TABLE

Journal: Immunity

Article Title: Diapedesis-induced integrin signalling via LFA-1 facilitates tissue immunity by inducing intrinsic complement C3 expression in immune cells

doi: 10.1016/j.immuni.2020.02.006

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Human recombinant EDIL3 (DEL1) , Abnova , Cat. #H00010085-P01.

Techniques: Virus, Generated, Control, Isolation, Recombinant, Purification, Staining, Diagnostic Assay, Cell Isolation, Enzyme-linked Immunosorbent Assay, Labeling, Gene Expression, Reverse Transcription, Synthesized, Software, Transfection, Imaging, Flow Cytometry, Microscopy, Western Blot